CAR-T therapy engineers a patient’s own immune cells to fight cancer. Making these cels more resilient can make treatments more effective.
Articles on CAR-T
Displaying all articles
CAR-T cell therapies advance the treatment of cancer, but they are expensive and can take weeks to process. Academic development could cut costs and time while making them more accessible.
A breakthrough therapy is driving aggressive leukaemia into remission. Here’s what the headlines don’t tell you about life after treatment.
The risk of getting a secondary cancer after Car-T cell therapy is low, a new study confirms.
From cancer immunotherapy and antibiotics to GMO crops and pandemic surveillance, gain of function is a cornerstone of basic research.
Immunotherapy has the potential to eliminate tumors, but works best for select patients. Engineering T cells to bypass cancer’s defenses could help expand treatment eligibility to more patients.
German doctors have reported success in treating patients with severe lupus, using cell treatments like those used for some forms of blood cancer.
CAR-T is a powerful new immunotherapy for treating leukaemia. We need to build on it to attack other, harder-to-treat cancers.
Top contributors
-
Professor of Biomedical Sciences, Anglia Ruskin University
-
Associate Professor of Microbiology and Immunology, Emory University
-
Head, School of Clincial Sciences at Monash Health, Monash University
-
Assistant Professor of Medicine, University of California, San Francisco
-
Associate Professor of Microbiology and Immunology at Emory University, University of Pittsburgh
-
PhD Candidate in Chemical Engineering, Université Laval
-
Professor of Cellular and Molecular Medicine, Florida International University
-
Senior Lecturer in Haematology, Immunolgy, Genetics and Evolution, University of Lancashire
-
Postdoctoral Associate in Cellular and Molecular Medicine, Florida International University